Table 3.
Treatment types and imaging information in response monitoring.
| Characteristicsa | Study groups | |||
|---|---|---|---|---|
| CE-CT (n = 144) | FDG-PET/CT (n = 83) | Combined (n = 73) | p-value | |
| Exposure of patients to treatment categories | ||||
| Endocrine therapy | 107 (74.3) | 61 (73.5) | 53 (72.6) | 0.97 |
| Chemotherapy | 99 (68.8) | 45 (54.2) | 57 (78.1) | 0.006 |
| Palliative radiotherapy | 32 (22.2) | 9 (10.9) | 12 (16.4) | 0.09 |
| Anti-HER2 therapyb | 13 (9.0) | 7 (8.4) | 17 (23.3) | 0.009 |
| CDK4/6 inhibitors | 19 (13.2) | 19 (22.9) | 12 (16.4) | 0.18 |
| Bone-target therapy | 105 (72.9) | 60 (72.3) | 52 (71.2) | 0.98 |
| No treatment / Unknown | 0 (0) | 1 (1.2) | 0 (0) | 0.52 |
| Protocolled experimental treatments | 15 (10.4) | 0 (0) | 13 (17.8) | <0.001 |
| Imaging information during follow-up period | ||||
| Total number of scans | 11 (3–36) | 11 (3–36) | 18 (5–51) | <0.001 |
| Number of scans per 3 months | 1.2 (0.4–3.6) | 1.1 (0.3–5.8) | 1.2 (0.2–2.7) | 0.40 |
| Patients experienced switch to opposite modality (once) | 37 (25.7) | 39 (47.0) | – | 0.001 |
| Performed MRI scans | 1 (0–8) | 1 (0–10) | 1 (0–9) | 0.26 |
CE-CT contrast-enhanced computed tomography, FDG-PET/CT Fluorodeoxyglucose positron emission tomography with integrated computed tomography, MRI magnetic resonance imaging, HER2 human epidermal growth factor receptor-2.
aData shown as frequency (%) at the patient level and as median (interquartile range) for performed scans.
bAnti-HER2 therapies consisted of Trastuzumab, Pertuzumab and T-DM1.
Statistically significant p < 0.05 values are in bold.